Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability

Asian Journal of Pharmaceutical Sciences

Volumn 9, Issue 6, 2014, Pages 304-316

  Khadka, Prakash ^a   Ro, Jieun ^a   Kim, Hyeongmin ^a   Kim, Iksoo ^a   Kim, Jeong Tae ^a   Kim, Hyunil ^a   Cho, Jae Min ^a   Yun, Gyiae ^a   Lee, Jaehwi ^a  

^a Chung Ang University   (South Korea)

Author keywords

Dissolution; Drug solubility; Particle technology; Poorly water soluble drug; Solubility enhancement

Indexed keywords

POLYMER; SOLID LIPID NANOPARTICLE;

BALL MILLING; COMPLEX FORMATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG PENETRATION; DRUG SOLUBILITY; FREEZE DRYING; HIGH PRESSURE HOMOGENIZATION; HUMAN; IN VITRO STUDY; JET MILLING; MECHANICAL MICRONIZATION; MICELLE; NONHUMAN; PARTICLE SIZE; PHARMACEUTICS; POWDER; REVIEW; SOLID PHARMACEUTICAL PARTICLE TECHNOLOGY; SOLID SELF EMULSIFYING DRUG DELIVERY SYSTEM; SURFACE PROPERTY;

EID: 84919921268     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2014.05.005     Document Type: Review

References (83)

1. Amidon G.L., Lennernas H., Shah V.P., et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of invitro drug product dissolution and invivo bioavailability. Pharm Res 1995, 12:413-420.
2. Williams H.D., Trevaskis N.L., Charman S.A., et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev 2013, 65:315-499.
3. Krishnaiah Y.S.R. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Bioavailab 2010, 2:28-36.
4. Kawabata Y., Wada K., Nakatani M., et al. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm 2011, 420:1-10.
5. Hu J., Johnston K.P., Williams R.O. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm 2004, 30:233-245.
6. Costa P., Sousa Lobo J.M. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001, 13:123-133.
7. Wagh M.P., Patel J.S. Biopharmaceutical classification system: scientific basis for biowaiver extensions. Int J Pharm Pharm Sci 2010, 2:12-19.
8. Yu L.X., Amidon G.L., Polli J.E., et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 2002, 19:921-925.
9. Kumar S., Bhargava D., Thakkar A., et al. Drug carrier systems for solubility enhancement of BCS class II drugs: a critical review. Crit Rev Ther Drug Carrier Syst 2013, 30:217-256.
10. Onoue S., Kojo Y., Aoki Y., et al. Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability. Drug Metab Pharmacokinet 2012, 27:379-387.
11. Urbanetz N.A. Stabilization of solid dispersions of nimodipine and polyethylene glycol 2000. Eur J Pharm Sci 2006, 28:67-76.
12. Fahr A., Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv 2007, 4:403-416.
13. Pouton C.W. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006, 29:278-287.
14. Leuenberger H., Lanz M. Pharmaceutical powder technology-from art to science: the challenge of the FDA's process analytical technology initiative. Adv Powder Technol 2005, 16:3-25.
15. Davé R.N., Bilgili E., Jallo L., et al. Special issue on pharmaceutical powders: towards developing understanding of the influence of materials and processes on product performance. Powder Technol 2013, 236:1-4.
16. Dressman J.B., Vertzoni M., Goumas K., et al. Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliv Rev 2007, 59:591-602.
17. Savjani K.T., Gajjar A.K., Savjani J.K. Drug solubility: importance and enhancement techniques. ISRN Pharm 2012, 1-10. 10.5402/2012/195727.
18. Leleux J., Williams R.O. Recent advancements in mechanical reduction methods: Particulate systems. Drug Dev Ind Pharm 2013, 3109:1-12.
19. Dokoumetzidis A., Macheras P. A century of dissolution research: from noyes and whitney to the biopharmaceutics classification system. Int J Pharm 2006, 321:1-11.
20. Sun J., Wang F., Sui Y., et al. Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q(10) as naked nanocrystals. Int J Nanomed 2012, 7:5733-5744.
21. Junghanns J.A., Müller R.H. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 2008, 3:295-309.
22. Merisko-Liversidge E., Liversidge G.G., Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003, 18:113-120.
23. Rawat N., Kumar M.S., Mahadevan N. Solubility: Particle size reduction is a promising approach to improve the bioavailability of lipophillic drugs. Int J Recent Adv Pharm Res 2011, 1:8-18.
24. Rasenack N., Muller B.W. Micron-size drug particles: common and novel micronization techniques. Pharm Dev Technol 2004, 9:1-13.
25. Midoux N., Hošek P., Pailleres L., et al. Micronization of pharmaceutical substances in a spiral jet mill. Powder Technol 1999, 104:113-120.
26. Jinno J., Kamada N., Miyake M., et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 2006, 111:56-64.
27. Han X., Ghoroi C., To D., et al. Simultaneous micronization and surface modification for improvement of flow and dissolution of drug particles. Int J Pharm 2011, 415:185-195.
28. Liversidge G.G., Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995, 125:91-97.
29. Graeser K.A., Patterson J.E., Zeitler J.A., et al. The role of configurational entropy in amorphous systems. Pharmaceutics 2010, 2:224-244.
30. Patterson J.E., James M.B., Forster A.H., et al. Preparation of glasssolutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling. Int J Pharm 2007, 336:22-34.
31. Kluge J., Muhrer G., Mazzotti M. High pressure homogenization of pharmaceutical solids. J Supercrit Fluid 2012, 66:380-388.
32. Keck C.M., Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006, 62:3-16.
33. Müller R.H., Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. preparation by a size-reduction technique. Int J Pharm 1998, 160:229-237.
34. Hecq J., Deleers M., Fanara D., et al. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm 2005, 299:167-177.
35. 2 with cosolvent acetone. Proc 6th Int Symp Supercrit Fluid 2003.
36. Kayrak D., Akman U., Hortaçsu Ö Micronization of ibuprofen by RESS. J Supercrit Fluid 2003, 26:17-31.
37. Koshy P., Pacharane S., Chaudhry A., et al. Drug particle engineering of poorly water soluble drugs. Der Pharm Let 2010, 2:65-76.
38. 2 and cryogenic spray-freezing technologies. Drug Dev Ind Pharm 2001, 27:1003-1015.
39. Rogers T.L., Nelsen A.C., Hu J., et al. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: Spray-freezing into liquid. Eur J Pharm Biopharm 2002, 54:271-280.
40. Rogers T.L., Nelsen A.C., Sarkari M., et al. Enhanced aqueous dissolution of a poorly water soluble drug by novel particleengineering technology: Spray-freezing into liquidwith atmospheric freeze-drying. Pharm Res 2003, 20:485-493.
41. Hu J., Johnston K.P., Williams R.O. Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur J Pharm Sci 2003, 20:295-303.
42. Purvis T., Vaughn J.M., Rogers T.L., et al. Cryogenic liquids, nanoparticles, and microencapsulation. Int J Pharm 2006, 324:43-50.
43. Blagden N., De Matas M., Gavan P., et al. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 2007, 59:617-630.
44. Deerle D., Patel J., Yeole D., et al. Particle engineering techniques to enhance dissolution of poorly water soluble drugs. Int J Cur Pharm Res 2010, 2:10-15.
45. McNamara D.P., Childs S.L., Giordano J., et al. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res 2006, 23:1888-1897.
46. Sajeev Kumar B., Saraswathi R., Venkates Kumar K., et al. Development and characterization of lecithin stabilized glibenclamide nanocrystals for enhanced solubility and drug delivery. Drug Deliv 2014, 21:173-184.
47. da Fonseca Antunes A.B., De Geest B.G., Vervaet C., et al. Solvent-free drug crystal engineering for drug nano-& micro suspensions. Eur J Pharm Sci 2013, 48:121-129.
48. Tang B., Cheng G., Gu J., et al. Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today 2008, 13:606-612.
49. Yi T., Wan J., Xu H., et al. A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs. Eur J Pharm Biopharm 2008, 70:439-444.
50. Kim D.W., Kang J.H., Oh D.H., et al. Development of novel flurbiprofen-loaded solid self-microemulsifying drug delivery system using gelatin as solid carrier. J Microencapsul 2012, 29:323-330.
51. Balakrishnan P., Lee B., Oh D.H., et al. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm 2009, 72:539-545.
52. Chen Y., Chen C., Zheng J., et al. Development of a solid supersaturatable self-emulsifying drug delivery system of docetaxel with improved dissolution and bioavailability. Biol Pharm Bull 2011, 34:278-286.
53. Yan Y., Kim J.A., Kwak M.K., et al. Enhanced oral bioavailability of curcumin via a solid lipid-based self-emulsifying drug delivery system using a spray-drying technique. Biol Pharm Bull 2011, 34:1179-1186.
54. Agarwal V., Alayoubi A., Siddiqui A., et al. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration. Drug Dev Ind Pharm 2013, 39:1681-1689.
55. Kanaujia P., Ng W.K., Tan R.B. Solid self-emulsifying drug delivery system (S-SEDDS) for improved dissolution rate of fenofibrate. J Microencapsul 2013, 31:293-298.
56. Kang M.J., Jung S.Y., Song W.H., et al. Immediate release of ibuprofen from Fujicalin®-based fast-dissolving self-emulsifying tablets. Drug Dev Ind Pharm 2011, 37:1298-1305.
57. Brewster M.E., Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007, 59:645-666.
58. Singh A., Worku Z.A., Van den Mooter G. Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin Drug Deliv 2011, 8:1361-1378.
59. Carrier R.L., Miller L.A., Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 2007, 123:78-99.
60. Rasheed A., Kumar A., Sravanthi V. Cyclodextrins as drug carrier molecule: a review. Sci Pharm 2008, 76:567-598.
61. Becket G., Schep L.J., Tan M.Y. Improvement of the invitrodissolution of praziquantel by complexation with alpha-, beta- and gamma-cyclodextrins. Int J Pharm 1999, 179:65-71.
62. Rawat S., Jain S.K. Solubility enhancement of celecoxib using β-cyclodextrin inclusion complexes. Eur J Pharm Biopharm 2004, 57:263-267.
63. Memişoğlu E., Bochot A., Özalp M., et al. Direct formation of nanospheres from amphiphilic β-cyclodextrin inclusion complexes. Pharm Res 2003, 20:117-125.
64. Bader H., Ringsdorf H., Schmidt B. Watersoluble polymers in medicine. Angew Makromol Chem 1984, 123:457-485.
65. Jones M., Leroux J. Polymeric micelles-a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999, 48:101-111.
66. Lukyanov A.N., Torchilin V.P. Micelles from lipid derivativesofwater-soluble polymers as delivery systems forpoorly soluble drugs. Adv Drug Deliv Rev 2004, 56:1273-1289.
67. Torchilin V. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci 2004, 61:2549-2559.
68. Gaucher G., Dufresne M., Sant V.P., et al. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005, 109:169-188.
69. Kwon G.S., Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev 1996, 21:107-116.
70. Lee S.C., Huh K.M., Lee J., et al. Hydrotropic polymeric micelles for enhanced paclitaxel solubility: Invitro and invivo characterization. Biomacromolecules 2007, 8:202-208.
71. Shin H., Alani A.W., Rao D.A., et al. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release 2009, 140:294-300.
72. Yu B., Okano T., Kataoka K., et al. Polymeric micelles for drug delivery: solubilization and haemolytic activity of amphotericin B. J Control Release 1998, 53:131-136.
73. Mohammed A., Weston N., Coombes A., et al. Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. Int J Pharm 2004, 285:23-34.
74. Zhang J.A., Anyarambhatla G., Ma L., et al. Development and characterization of a novel cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 2005, 59:177-187.
75. Crowe L.M., Crowe J.H., Rudolph A., et al. Preservation of freeze-dried liposomes by trehalose. Arch Biochem Biophys 1985, 242:240-247.
76. Ghanbarzadeh S., Valizadeh H., Zakeri-Milani P. The effects of lyophilization on the physico-chemical stability of sirolimus liposomes. Adv Pharm Bull 2013, 3:25-29.
77. Yang T., Cui F., Choi M., et al. Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv 2007, 14:301-308.
78. Yang T., Cui F., Choi M., et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: invitro and invivo evaluation. Int J Pharm 2007, 338:317-326.
79. Üner M., Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomed 2007, 2:289-300.
80. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000, 50:161-177.
81. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001, 47:165-196.
82. Hu L., Tang X., Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol 2004, 56:1527-1535.
83. Das S., Ng W.K., Kanaujia P., et al. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerfaces 2011, 88:483-489.